 William Robinson
Concepts (766)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 89 | 2023 | 620 | 7.190 |
Why?
| | Skin Neoplasms | 44 | 2022 | 754 | 3.590 |
Why?
| | Proto-Oncogene Proteins c-kit | 6 | 2019 | 63 | 1.780 |
Why?
| | Mastocytosis | 3 | 2021 | 12 | 1.520 |
Why?
| | Antineoplastic Agents | 18 | 2021 | 1875 | 1.140 |
Why?
| | Mutation | 17 | 2022 | 3338 | 0.880 |
Why?
| | Antibodies, Monoclonal | 7 | 2018 | 1257 | 0.840 |
Why?
| | Osteoporotic Fractures | 2 | 2020 | 54 | 0.780 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.730 |
Why?
| | Piperazines | 7 | 2018 | 310 | 0.720 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2019 | 43 | 0.690 |
Why?
| | Middle Aged | 87 | 2022 | 26621 | 0.690 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2018 | 178 | 0.640 |
Why?
| | Exome | 2 | 2017 | 200 | 0.640 |
Why?
| | Spinal Fractures | 1 | 2020 | 74 | 0.630 |
Why?
| | Esophageal Achalasia | 1 | 2019 | 25 | 0.630 |
Why?
| | Histiocytosis, Sinus | 1 | 2018 | 7 | 0.600 |
Why?
| | Neurofibromin 1 | 2 | 2017 | 22 | 0.600 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 131 | 0.600 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2013 | 57 | 0.590 |
Why?
| | Humans | 188 | 2023 | 114080 | 0.590 |
Why?
| | Orthopedics | 1 | 2020 | 120 | 0.590 |
Why?
| | Humeral Head | 1 | 2017 | 13 | 0.590 |
Why?
| | Osteoporosis | 2 | 2020 | 224 | 0.590 |
Why?
| | Arthroplasty, Replacement, Shoulder | 1 | 2017 | 20 | 0.580 |
Why?
| | Databases, Factual | 4 | 2020 | 1127 | 0.580 |
Why?
| | Intention | 1 | 2019 | 142 | 0.570 |
Why?
| | Carcinoma, Merkel Cell | 2 | 2008 | 17 | 0.570 |
Why?
| | Vitiligo | 4 | 2020 | 41 | 0.570 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 49 | 0.550 |
Why?
| | Proto-Oncogene Proteins B-raf | 6 | 2020 | 191 | 0.540 |
Why?
| | Genetic Predisposition to Disease | 4 | 2019 | 2090 | 0.540 |
Why?
| | MicroRNAs | 4 | 2023 | 600 | 0.540 |
Why?
| | Mucous Membrane | 1 | 2017 | 108 | 0.530 |
Why?
| | Female | 110 | 2022 | 59349 | 0.530 |
Why?
| | Forecasting | 2 | 2017 | 331 | 0.520 |
Why?
| | Spinal Fusion | 1 | 2019 | 199 | 0.520 |
Why?
| | Biomarkers, Tumor | 8 | 2019 | 1032 | 0.520 |
Why?
| | Aged | 62 | 2021 | 18973 | 0.510 |
Why?
| | Shoulder Joint | 1 | 2017 | 158 | 0.510 |
Why?
| | Osteoarthritis | 1 | 2017 | 169 | 0.500 |
Why?
| | Sentinel Lymph Node Biopsy | 7 | 2021 | 99 | 0.500 |
Why?
| | Adult | 85 | 2021 | 30395 | 0.500 |
Why?
| | Hematopoiesis | 22 | 1988 | 170 | 0.500 |
Why?
| | Aged, 80 and over | 21 | 2021 | 6307 | 0.490 |
Why?
| | Pyrimidines | 4 | 2008 | 374 | 0.490 |
Why?
| | Phosphoproteins | 1 | 2017 | 293 | 0.490 |
Why?
| | Neoplasms, Second Primary | 3 | 2023 | 92 | 0.480 |
Why?
| | Melanocytes | 5 | 2020 | 55 | 0.480 |
Why?
| | Granulocytes | 24 | 1988 | 75 | 0.460 |
Why?
| | Ultraviolet Therapy | 3 | 2020 | 16 | 0.440 |
Why?
| | Male | 89 | 2022 | 55420 | 0.440 |
Why?
| | Cell Line, Tumor | 17 | 2018 | 2699 | 0.440 |
Why?
| | Microphthalmia-Associated Transcription Factor | 3 | 2008 | 14 | 0.430 |
Why?
| | Nevus | 3 | 2010 | 26 | 0.420 |
Why?
| | Neoplastic Stem Cells | 5 | 2018 | 327 | 0.420 |
Why?
| | Milk, Human | 1 | 2014 | 127 | 0.410 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2023 | 1356 | 0.410 |
Why?
| | Colony-Stimulating Factors | 19 | 1988 | 32 | 0.400 |
Why?
| | Breast Neoplasms | 8 | 2017 | 1846 | 0.400 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2012 | 27 | 0.390 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2018 | 1144 | 0.380 |
Why?
| | Military Personnel | 1 | 2019 | 522 | 0.380 |
Why?
| | Pyrroles | 3 | 2021 | 181 | 0.380 |
Why?
| | Triazines | 2 | 2021 | 36 | 0.370 |
Why?
| | Sulfonamides | 4 | 2020 | 444 | 0.360 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2008 | 59 | 0.360 |
Why?
| | Lymph Node Excision | 5 | 2021 | 140 | 0.350 |
Why?
| | Adenocarcinoma | 5 | 2016 | 787 | 0.350 |
Why?
| | Lymphatic Metastasis | 7 | 2013 | 275 | 0.350 |
Why?
| | Sentinel Lymph Node | 2 | 2021 | 37 | 0.350 |
Why?
| | Skin Pigmentation | 3 | 2020 | 39 | 0.340 |
Why?
| | Myeloid-Derived Suppressor Cells | 2 | 2023 | 56 | 0.340 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2018 | 437 | 0.330 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2020 | 22 | 0.320 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2022 | 152 | 0.310 |
Why?
| | RNA, Neoplasm | 2 | 2008 | 80 | 0.310 |
Why?
| | Immunohistochemistry | 6 | 2019 | 1624 | 0.310 |
Why?
| | Sarcoma, Clear Cell | 1 | 2008 | 8 | 0.300 |
Why?
| | Pyrazoles | 2 | 2021 | 361 | 0.300 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2008 | 18 | 0.300 |
Why?
| | Cyclins | 1 | 2008 | 78 | 0.290 |
Why?
| | Nitrophenols | 3 | 2017 | 32 | 0.290 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 40 | 0.290 |
Why?
| | Tretinoin | 4 | 2023 | 122 | 0.290 |
Why?
| | Genes, p16 | 2 | 2007 | 16 | 0.280 |
Why?
| | Biphenyl Compounds | 3 | 2017 | 50 | 0.280 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 307 | 0.280 |
Why?
| | Tamoxifen | 3 | 2016 | 190 | 0.280 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 30 | 0.270 |
Why?
| | GTP Phosphohydrolases | 4 | 2020 | 65 | 0.270 |
Why?
| | Prognosis | 13 | 2023 | 3315 | 0.260 |
Why?
| | Treatment Outcome | 11 | 2020 | 9051 | 0.260 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2018 | 695 | 0.260 |
Why?
| | Tumor Suppressor Proteins | 3 | 2015 | 283 | 0.260 |
Why?
| | Interferon-alpha | 6 | 2006 | 185 | 0.250 |
Why?
| | Follow-Up Studies | 12 | 2020 | 4392 | 0.250 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 5 | 2021 | 211 | 0.250 |
Why?
| | Leukocytes | 12 | 1986 | 272 | 0.250 |
Why?
| | DNA, Neoplasm | 5 | 2017 | 155 | 0.240 |
Why?
| | Liposarcoma | 1 | 2005 | 25 | 0.240 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2023 | 337 | 0.240 |
Why?
| | Polymerase Chain Reaction | 6 | 2008 | 990 | 0.230 |
Why?
| | Piperidines | 2 | 2018 | 159 | 0.230 |
Why?
| | Lymph Nodes | 1 | 2006 | 415 | 0.230 |
Why?
| | Neoplasm Staging | 10 | 2019 | 1162 | 0.230 |
Why?
| | Melatonin | 3 | 1994 | 106 | 0.220 |
Why?
| | Exons | 3 | 2019 | 301 | 0.220 |
Why?
| | Dacarbazine | 7 | 2012 | 99 | 0.220 |
Why?
| | Mice, Nude | 4 | 2020 | 628 | 0.220 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2016 | 637 | 0.220 |
Why?
| | Stem Cells | 4 | 2017 | 541 | 0.220 |
Why?
| | Hair Follicle | 3 | 2020 | 44 | 0.220 |
Why?
| | Flavonoids | 1 | 2003 | 66 | 0.210 |
Why?
| | HLA-DR Antigens | 2 | 2022 | 219 | 0.210 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2016 | 850 | 0.210 |
Why?
| | Chromosome Aberrations | 2 | 1994 | 134 | 0.210 |
Why?
| | Genes, erbB-1 | 2 | 2016 | 17 | 0.210 |
Why?
| | Lysophospholipids | 1 | 2023 | 65 | 0.210 |
Why?
| | Mice | 25 | 2021 | 14847 | 0.200 |
Why?
| | Hematopoietic Stem Cells | 11 | 1986 | 338 | 0.200 |
Why?
| | Registries | 3 | 2020 | 1764 | 0.200 |
Why?
| | Risk Factors | 8 | 2020 | 8612 | 0.200 |
Why?
| | Mastocytosis, Systemic | 1 | 2021 | 6 | 0.190 |
Why?
| | Clone Cells | 7 | 2010 | 247 | 0.190 |
Why?
| | Genomics | 3 | 2022 | 631 | 0.190 |
Why?
| | Burns | 6 | 1997 | 237 | 0.190 |
Why?
| | Cell Cycle Proteins | 3 | 2007 | 549 | 0.190 |
Why?
| | Transcription, Genetic | 5 | 2017 | 1310 | 0.180 |
Why?
| | Drug Therapy, Combination | 5 | 2016 | 949 | 0.180 |
Why?
| | Sonication | 1 | 2020 | 10 | 0.170 |
Why?
| | Leukemia | 8 | 1988 | 208 | 0.170 |
Why?
| | Turner Syndrome | 1 | 2001 | 45 | 0.170 |
Why?
| | Adult Stem Cells | 1 | 2020 | 32 | 0.170 |
Why?
| | Interleukin-1 | 2 | 2019 | 965 | 0.170 |
Why?
| | Laser Capture Microdissection | 2 | 2017 | 23 | 0.170 |
Why?
| | Aniline Compounds | 1 | 2020 | 70 | 0.170 |
Why?
| | Tissue Culture Techniques | 1 | 2020 | 66 | 0.170 |
Why?
| | Thoracic Vertebrae | 1 | 2020 | 68 | 0.170 |
Why?
| | RNA | 2 | 2016 | 806 | 0.170 |
Why?
| | Tumor Cells, Cultured | 6 | 2003 | 845 | 0.170 |
Why?
| | beta Catenin | 2 | 2020 | 218 | 0.170 |
Why?
| | Signal Transduction | 7 | 2023 | 4501 | 0.160 |
Why?
| | Sequence Analysis, RNA | 3 | 2018 | 388 | 0.160 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 70 | 0.160 |
Why?
| | Animals | 29 | 2021 | 31570 | 0.160 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 66 | 0.160 |
Why?
| | Nomograms | 1 | 2019 | 41 | 0.160 |
Why?
| | Bone Density | 2 | 2020 | 432 | 0.160 |
Why?
| | Retrospective Studies | 13 | 2021 | 12521 | 0.160 |
Why?
| | Cervical Vertebrae | 1 | 2020 | 104 | 0.160 |
Why?
| | Heart Neoplasms | 2 | 1999 | 49 | 0.160 |
Why?
| | Prostheses and Implants | 1 | 2020 | 135 | 0.160 |
Why?
| | Molecular Targeted Therapy | 2 | 2019 | 347 | 0.160 |
Why?
| | Visual Analog Scale | 1 | 2019 | 30 | 0.160 |
Why?
| | Case-Control Studies | 5 | 2022 | 3007 | 0.160 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2018 | 43 | 0.160 |
Why?
| | Lumbosacral Region | 1 | 2019 | 45 | 0.160 |
Why?
| | CDC2 Protein Kinase | 1 | 2018 | 25 | 0.150 |
Why?
| | Ipilimumab | 1 | 2018 | 27 | 0.150 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 207 | 0.150 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 60 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 687 | 0.150 |
Why?
| | Gene Expression Profiling | 4 | 2018 | 1519 | 0.150 |
Why?
| | Pedigree | 2 | 2019 | 460 | 0.150 |
Why?
| | Hospital Costs | 1 | 2018 | 104 | 0.150 |
Why?
| | Biofilms | 1 | 2020 | 223 | 0.150 |
Why?
| | Septins | 1 | 2018 | 40 | 0.150 |
Why?
| | Leukemia, Myeloid | 10 | 1984 | 40 | 0.150 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 21 | 0.150 |
Why?
| | Imatinib Mesylate | 2 | 2008 | 63 | 0.140 |
Why?
| | Receptors, Androgen | 1 | 1998 | 131 | 0.140 |
Why?
| | Ultraviolet Rays | 2 | 2022 | 363 | 0.140 |
Why?
| | Cisplatin | 4 | 2006 | 262 | 0.140 |
Why?
| | Low Back Pain | 1 | 2019 | 93 | 0.140 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 171 | 0.140 |
Why?
| | Brain Neoplasms | 4 | 1994 | 966 | 0.140 |
Why?
| | Membrane Proteins | 4 | 2020 | 1016 | 0.140 |
Why?
| | Adenine | 1 | 2018 | 218 | 0.140 |
Why?
| | Databases, Genetic | 1 | 2018 | 206 | 0.140 |
Why?
| | Proto-Oncogene Proteins | 2 | 2018 | 607 | 0.140 |
Why?
| | Adolescent | 33 | 2020 | 17811 | 0.140 |
Why?
| | Benzamides | 2 | 2008 | 168 | 0.140 |
Why?
| | Secondary Prevention | 1 | 2018 | 221 | 0.140 |
Why?
| | Bone Marrow Cells | 16 | 1983 | 266 | 0.140 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 10 | 0.140 |
Why?
| | Lung Neoplasms | 7 | 2016 | 2159 | 0.130 |
Why?
| | Pain Measurement | 1 | 2019 | 441 | 0.130 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 213 | 0.130 |
Why?
| | Antigens, Neoplasm | 5 | 2005 | 222 | 0.130 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 1994 | 94 | 0.130 |
Why?
| | Bone Marrow Transplantation | 10 | 1986 | 237 | 0.130 |
Why?
| | Colony-Forming Units Assay | 18 | 1988 | 88 | 0.130 |
Why?
| | Freezing | 4 | 2014 | 84 | 0.130 |
Why?
| | Protein Isoforms | 1 | 2017 | 337 | 0.130 |
Why?
| | Preservation, Biological | 3 | 2014 | 7 | 0.130 |
Why?
| | Carrier Proteins | 2 | 2000 | 694 | 0.130 |
Why?
| | Bone Marrow | 13 | 1983 | 243 | 0.130 |
Why?
| | Drug Synergism | 4 | 2018 | 315 | 0.130 |
Why?
| | Genes, Tumor Suppressor | 1 | 1996 | 77 | 0.130 |
Why?
| | Apoptosis | 4 | 2018 | 2349 | 0.130 |
Why?
| | Head and Neck Neoplasms | 3 | 2013 | 427 | 0.130 |
Why?
| | Interferon Type I | 4 | 1994 | 128 | 0.130 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1078 | 0.130 |
Why?
| | Cell Cycle | 3 | 2010 | 541 | 0.130 |
Why?
| | Lentigo | 1 | 2015 | 5 | 0.120 |
Why?
| | Reoperation | 1 | 2017 | 513 | 0.120 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2014 | 102 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2011 | 924 | 0.120 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2006 | 57 | 0.120 |
Why?
| | Radiography | 1 | 2017 | 803 | 0.120 |
Why?
| | Lymphoma | 4 | 1991 | 176 | 0.120 |
Why?
| | Leukocyte Count | 20 | 1988 | 292 | 0.120 |
Why?
| | Oligopeptides | 1 | 2016 | 234 | 0.120 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2018 | 246 | 0.120 |
Why?
| | Myeloproliferative Disorders | 1 | 1995 | 26 | 0.120 |
Why?
| | Fenretinide | 1 | 2014 | 7 | 0.120 |
Why?
| | Survival Analysis | 6 | 2010 | 1206 | 0.120 |
Why?
| | Desiccation | 1 | 2014 | 17 | 0.120 |
Why?
| | Peptides | 2 | 2008 | 847 | 0.120 |
Why?
| | Cell Survival | 8 | 2018 | 1014 | 0.120 |
Why?
| | Cell Division | 11 | 1998 | 754 | 0.120 |
Why?
| | Peptide Fragments | 1 | 2018 | 665 | 0.120 |
Why?
| | Receptors, Estrogen | 1 | 2016 | 371 | 0.110 |
Why?
| | Perineum | 1 | 1993 | 25 | 0.110 |
Why?
| | Internet | 1 | 2018 | 591 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2021 | 1837 | 0.110 |
Why?
| | Cell Proliferation | 5 | 2018 | 2173 | 0.110 |
Why?
| | Basigin | 1 | 2013 | 25 | 0.110 |
Why?
| | Ear, External | 1 | 2013 | 22 | 0.110 |
Why?
| | Decision Making | 1 | 2019 | 760 | 0.110 |
Why?
| | Mohs Surgery | 1 | 2013 | 24 | 0.110 |
Why?
| | Extracellular Space | 1 | 2013 | 116 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 118 | 0.100 |
Why?
| | Sweat Gland Neoplasms | 1 | 2012 | 5 | 0.100 |
Why?
| | Alleles | 2 | 2022 | 789 | 0.100 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1992 | 56 | 0.100 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 1992 | 57 | 0.100 |
Why?
| | Alcohol Oxidoreductases | 1 | 2013 | 37 | 0.100 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2017 | 308 | 0.100 |
Why?
| | BRCA1 Protein | 1 | 2013 | 56 | 0.100 |
Why?
| | Vitamins | 1 | 1994 | 150 | 0.100 |
Why?
| | Child | 15 | 2020 | 18408 | 0.100 |
Why?
| | Side-Population Cells | 1 | 2012 | 9 | 0.100 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2013 | 153 | 0.100 |
Why?
| | Bone Marrow Diseases | 3 | 1983 | 18 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2540 | 0.100 |
Why?
| | Sequence Analysis, DNA | 2 | 2005 | 722 | 0.100 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 577 | 0.100 |
Why?
| | Escherichia coli Infections | 4 | 1981 | 102 | 0.100 |
Why?
| | Ricin | 1 | 1991 | 8 | 0.100 |
Why?
| | Immunotoxins | 1 | 1991 | 33 | 0.100 |
Why?
| | Neoplasms | 5 | 2018 | 2089 | 0.100 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 373 | 0.090 |
Why?
| | Complement C1q | 1 | 2011 | 36 | 0.090 |
Why?
| | Immune Tolerance | 2 | 1991 | 321 | 0.090 |
Why?
| | Cyclosporine | 1 | 1991 | 161 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2006 | 1791 | 0.090 |
Why?
| | Cohort Studies | 2 | 2019 | 4885 | 0.090 |
Why?
| | Quality Improvement | 1 | 2018 | 945 | 0.090 |
Why?
| | Pancreatitis | 1 | 1991 | 105 | 0.090 |
Why?
| | Agranulocytosis | 6 | 1986 | 31 | 0.090 |
Why?
| | Risk Assessment | 1 | 2019 | 2958 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2273 | 0.090 |
Why?
| | Blast Crisis | 1 | 1990 | 20 | 0.090 |
Why?
| | Bacterial Infections | 4 | 1989 | 217 | 0.090 |
Why?
| | Vitamin E | 2 | 1994 | 110 | 0.080 |
Why?
| | Disease-Free Survival | 5 | 2019 | 618 | 0.080 |
Why?
| | Cell Differentiation | 7 | 2015 | 1696 | 0.080 |
Why?
| | Neutrophils | 8 | 1988 | 1089 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2013 | 673 | 0.080 |
Why?
| | Recombinant Proteins | 7 | 1994 | 1228 | 0.080 |
Why?
| | Indium Radioisotopes | 1 | 1989 | 13 | 0.080 |
Why?
| | Transforming Growth Factor beta | 3 | 2019 | 445 | 0.080 |
Why?
| | Inflammation | 1 | 2019 | 2465 | 0.080 |
Why?
| | Cells, Cultured | 11 | 2019 | 3862 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 660 | 0.080 |
Why?
| | Lithium | 5 | 1986 | 36 | 0.080 |
Why?
| | Transcription Factors | 1 | 1996 | 1526 | 0.080 |
Why?
| | ErbB Receptors | 2 | 2013 | 554 | 0.080 |
Why?
| | Cyclin D | 1 | 2008 | 5 | 0.080 |
Why?
| | Computational Biology | 3 | 2019 | 528 | 0.080 |
Why?
| | Survival Rate | 7 | 2013 | 1638 | 0.080 |
Why?
| | S Phase | 1 | 2008 | 69 | 0.070 |
Why?
| | Base Sequence | 2 | 2011 | 2114 | 0.070 |
Why?
| | Up-Regulation | 3 | 2019 | 802 | 0.070 |
Why?
| | Australia | 2 | 2023 | 205 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2008 | 166 | 0.070 |
Why?
| | Cell Movement | 5 | 2015 | 863 | 0.070 |
Why?
| | Factor VIII | 1 | 1987 | 52 | 0.070 |
Why?
| | Receptor, Notch2 | 2 | 2020 | 14 | 0.070 |
Why?
| | Glucuronidase | 1 | 2007 | 42 | 0.070 |
Why?
| | Disease Progression | 2 | 2013 | 2371 | 0.070 |
Why?
| | Oligosaccharides | 1 | 2007 | 46 | 0.070 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 129 | 0.070 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2007 | 11 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 206 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3039 | 0.070 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2007 | 8 | 0.070 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 12 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2010 | 445 | 0.070 |
Why?
| | Neoadjuvant Therapy | 2 | 2006 | 305 | 0.070 |
Why?
| | Education, Medical | 1 | 1990 | 214 | 0.070 |
Why?
| | United States | 2 | 2020 | 12144 | 0.070 |
Why?
| | Cell Self Renewal | 2 | 2017 | 49 | 0.070 |
Why?
| | Chromosome Mapping | 1 | 2008 | 486 | 0.070 |
Why?
| | Hemophilia A | 1 | 1987 | 67 | 0.070 |
Why?
| | Time Factors | 13 | 2014 | 6077 | 0.070 |
Why?
| | Vaccinia virus | 2 | 1998 | 27 | 0.070 |
Why?
| | Health Education | 1 | 1990 | 317 | 0.070 |
Why?
| | Myelodysplastic Syndromes | 1 | 1988 | 119 | 0.070 |
Why?
| | Binding Sites | 2 | 2008 | 1166 | 0.070 |
Why?
| | Quinazolines | 1 | 2008 | 240 | 0.070 |
Why?
| | Infant | 2 | 2019 | 7946 | 0.070 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1311 | 0.060 |
Why?
| | Genome, Human | 1 | 2008 | 347 | 0.060 |
Why?
| | Immunotherapy, Adoptive | 2 | 1998 | 184 | 0.060 |
Why?
| | PTEN Phosphohydrolase | 1 | 2007 | 140 | 0.060 |
Why?
| | Viral Vaccines | 2 | 1998 | 88 | 0.060 |
Why?
| | Spinal Cord Compression | 1 | 1985 | 17 | 0.060 |
Why?
| | Hypercalcemia | 1 | 1985 | 19 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 1991 | 538 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2008 | 489 | 0.060 |
Why?
| | Diphosphonates | 1 | 2006 | 51 | 0.060 |
Why?
| | Vena Cava, Superior | 1 | 1985 | 23 | 0.060 |
Why?
| | Models, Biological | 3 | 2019 | 1611 | 0.060 |
Why?
| | Lymphocytes | 5 | 2006 | 327 | 0.060 |
Why?
| | Neoplasm Invasiveness | 3 | 2018 | 438 | 0.060 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2005 | 22 | 0.060 |
Why?
| | Testicular Neoplasms | 2 | 1984 | 96 | 0.060 |
Why?
| | In Vitro Techniques | 5 | 2012 | 1003 | 0.060 |
Why?
| | Karyotyping | 4 | 1994 | 100 | 0.060 |
Why?
| | Acute Disease | 6 | 1991 | 909 | 0.060 |
Why?
| | Axilla | 1 | 2004 | 39 | 0.060 |
Why?
| | Neoplasm Metastasis | 4 | 2007 | 521 | 0.060 |
Why?
| | Protein Transport | 2 | 2018 | 391 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 1880 | 0.060 |
Why?
| | Ki-67 Antigen | 1 | 2004 | 102 | 0.060 |
Why?
| | Phosphorylation | 2 | 2018 | 1559 | 0.060 |
Why?
| | Immunoenzyme Techniques | 1 | 2004 | 192 | 0.060 |
Why?
| | Blood Cell Count | 5 | 1995 | 50 | 0.060 |
Why?
| | Macrophages | 3 | 1988 | 1259 | 0.060 |
Why?
| | Genetic Testing | 1 | 2007 | 381 | 0.060 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 51 | 0.060 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 372 | 0.050 |
Why?
| | Urine | 4 | 1973 | 54 | 0.050 |
Why?
| | Age Distribution | 2 | 2018 | 341 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 784 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 23 | 0.050 |
Why?
| | Inhibitory Concentration 50 | 1 | 2003 | 74 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 29 | 0.050 |
Why?
| | Schistosoma | 1 | 1983 | 18 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2783 | 0.050 |
Why?
| | Carcinoma, Transitional Cell | 1 | 1983 | 53 | 0.050 |
Why?
| | Glycoproteins | 4 | 1977 | 304 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 103 | 0.050 |
Why?
| | Neutropenia | 3 | 1980 | 123 | 0.050 |
Why?
| | Smoking | 1 | 1990 | 1382 | 0.050 |
Why?
| | Young Adult | 4 | 2020 | 10459 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 76 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 1984 | 247 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 2018 | 3499 | 0.050 |
Why?
| | Clinical Trials as Topic | 4 | 2018 | 926 | 0.050 |
Why?
| | Incidence | 3 | 2009 | 2314 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 8 | 0.050 |
Why?
| | Antigens | 2 | 1983 | 317 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 45 | 0.050 |
Why?
| | Leukocytosis | 4 | 1974 | 34 | 0.050 |
Why?
| | Gene Expression | 3 | 2008 | 1417 | 0.050 |
Why?
| | Bone Neoplasms | 1 | 1983 | 191 | 0.050 |
Why?
| | Isotretinoin | 2 | 1994 | 22 | 0.050 |
Why?
| | PAX3 Transcription Factor | 2 | 2015 | 11 | 0.050 |
Why?
| | Paired Box Transcription Factors | 2 | 2015 | 36 | 0.050 |
Why?
| | Administration, Oral | 5 | 1995 | 725 | 0.050 |
Why?
| | Urinary Bladder Neoplasms | 1 | 1983 | 196 | 0.050 |
Why?
| | Eosinophils | 1 | 1983 | 276 | 0.050 |
Why?
| | Smallpox Vaccine | 2 | 1998 | 22 | 0.050 |
Why?
| | Leukemia, Myeloid, Acute | 4 | 1984 | 533 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2003 | 496 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2000 | 14 | 0.040 |
Why?
| | Escherichia coli | 2 | 1983 | 723 | 0.040 |
Why?
| | Leukemia, Lymphoid | 6 | 1979 | 27 | 0.040 |
Why?
| | Enterobacter cloacae | 1 | 2020 | 3 | 0.040 |
Why?
| | Mycobacterium chelonae | 1 | 2020 | 8 | 0.040 |
Why?
| | Gene Amplification | 1 | 2020 | 95 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2019 | 2550 | 0.040 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2020 | 48 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 94 | 0.040 |
Why?
| | Tetracycline | 1 | 2000 | 11 | 0.040 |
Why?
| | Oxidoreductases | 1 | 2020 | 89 | 0.040 |
Why?
| | Tocopherols | 2 | 1994 | 22 | 0.040 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 61 | 0.040 |
Why?
| | Gene Dosage | 1 | 2020 | 129 | 0.040 |
Why?
| | Monocytes | 3 | 1983 | 503 | 0.040 |
Why?
| | Chromosomes, Human, 6-12 and X | 2 | 1994 | 5 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2003 | 743 | 0.040 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 959 | 0.040 |
Why?
| | Endotoxins | 2 | 1978 | 211 | 0.040 |
Why?
| | Data Curation | 1 | 2019 | 11 | 0.040 |
Why?
| | Germ-Free Life | 1 | 1979 | 28 | 0.040 |
Why?
| | Vincristine | 3 | 1984 | 99 | 0.040 |
Why?
| | Mast Cells | 1 | 2020 | 117 | 0.040 |
Why?
| | Cyclophosphamide | 3 | 1983 | 214 | 0.040 |
Why?
| | Aneuploidy | 2 | 1994 | 84 | 0.040 |
Why?
| | Keratinocytes | 1 | 2020 | 215 | 0.040 |
Why?
| | Dysplastic Nevus Syndrome | 1 | 1998 | 2 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2019 | 88 | 0.040 |
Why?
| | Erythropoietin | 3 | 1982 | 72 | 0.040 |
Why?
| | Injections, Subcutaneous | 5 | 2007 | 134 | 0.040 |
Why?
| | Azetidines | 1 | 2018 | 31 | 0.040 |
Why?
| | Dynamins | 1 | 2018 | 29 | 0.040 |
Why?
| | Oncostatin M | 1 | 1998 | 6 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 429 | 0.040 |
Why?
| | Phenotype | 3 | 2015 | 2784 | 0.040 |
Why?
| | Echocardiography, Transesophageal | 1 | 1999 | 90 | 0.040 |
Why?
| | Heterografts | 1 | 2018 | 117 | 0.040 |
Why?
| | Chromosome Deletion | 2 | 1994 | 94 | 0.040 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 170 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 532 | 0.040 |
Why?
| | Levamisole | 1 | 1977 | 19 | 0.040 |
Why?
| | Bone Density Conservation Agents | 1 | 2018 | 62 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2019 | 339 | 0.040 |
Why?
| | Drug Approval | 1 | 2018 | 78 | 0.040 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2017 | 37 | 0.040 |
Why?
| | Sex Distribution | 1 | 2018 | 336 | 0.040 |
Why?
| | Drug Utilization | 1 | 2018 | 164 | 0.040 |
Why?
| | Precancerous Conditions | 1 | 1998 | 155 | 0.040 |
Why?
| | Skilled Nursing Facilities | 1 | 2018 | 121 | 0.030 |
Why?
| | Anesthesia | 1 | 2018 | 117 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2017 | 98 | 0.030 |
Why?
| | Drug Evaluation | 4 | 1991 | 77 | 0.030 |
Why?
| | Felty Syndrome | 4 | 1980 | 4 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2018 | 149 | 0.030 |
Why?
| | Genes, p53 | 1 | 1997 | 61 | 0.030 |
Why?
| | CD146 Antigen | 1 | 2016 | 35 | 0.030 |
Why?
| | Menopause | 2 | 2006 | 271 | 0.030 |
Why?
| | Thioguanine | 2 | 1984 | 19 | 0.030 |
Why?
| | Carmustine | 3 | 1986 | 47 | 0.030 |
Why?
| | Cicatrix | 1 | 1997 | 49 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2003 | 913 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2016 | 105 | 0.030 |
Why?
| | Thrombocytopenia | 4 | 2007 | 177 | 0.030 |
Why?
| | Cytarabine | 2 | 1984 | 51 | 0.030 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2016 | 72 | 0.030 |
Why?
| | Cancer Vaccines | 1 | 1997 | 137 | 0.030 |
Why?
| | Hodgkin Disease | 4 | 1985 | 121 | 0.030 |
Why?
| | Combined Modality Therapy | 3 | 1998 | 1117 | 0.030 |
Why?
| | Splenomegaly | 2 | 1995 | 16 | 0.030 |
Why?
| | Vinblastine | 2 | 2006 | 63 | 0.030 |
Why?
| | Interleukin-2 | 3 | 2006 | 413 | 0.030 |
Why?
| | Drug Administration Schedule | 4 | 2007 | 714 | 0.030 |
Why?
| | Protein Binding | 2 | 2018 | 1888 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 138 | 0.030 |
Why?
| | Mercaptopurine | 2 | 1972 | 15 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 153 | 0.030 |
Why?
| | Inpatients | 1 | 2018 | 378 | 0.030 |
Why?
| | Lymphatic Diseases | 1 | 1995 | 17 | 0.030 |
Why?
| | Gene Deletion | 1 | 1997 | 356 | 0.030 |
Why?
| | Veins | 1 | 1995 | 55 | 0.030 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2015 | 57 | 0.030 |
Why?
| | Surgeons | 1 | 2018 | 236 | 0.030 |
Why?
| | Infusions, Intravenous | 2 | 1995 | 370 | 0.030 |
Why?
| | Primary Myelofibrosis | 1 | 1974 | 9 | 0.030 |
Why?
| | Polycythemia Vera | 1 | 1974 | 12 | 0.030 |
Why?
| | Retinoids | 1 | 2014 | 31 | 0.030 |
Why?
| | Genetic Linkage | 1 | 2015 | 294 | 0.030 |
Why?
| | Proteinuria | 1 | 1974 | 77 | 0.030 |
Why?
| | Random Allocation | 3 | 1990 | 328 | 0.030 |
Why?
| | Culture Techniques | 4 | 1979 | 78 | 0.030 |
Why?
| | Epidermis | 1 | 2015 | 148 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1361 | 0.030 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 1994 | 4 | 0.030 |
Why?
| | Catheterization, Central Venous | 1 | 1995 | 83 | 0.030 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 1994 | 16 | 0.030 |
Why?
| | beta Carotene | 1 | 1994 | 18 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 1994 | 24 | 0.030 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 1994 | 49 | 0.030 |
Why?
| | Estrogens | 1 | 2016 | 312 | 0.030 |
Why?
| | Vaginal Neoplasms | 1 | 1993 | 11 | 0.030 |
Why?
| | Carotenoids | 1 | 1994 | 33 | 0.030 |
Why?
| | Vulvar Neoplasms | 1 | 1993 | 10 | 0.030 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 1994 | 31 | 0.030 |
Why?
| | Vitamin B 12 | 1 | 1974 | 115 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2016 | 428 | 0.030 |
Why?
| | Anus Neoplasms | 1 | 1993 | 24 | 0.030 |
Why?
| | Translocation, Genetic | 1 | 1994 | 92 | 0.030 |
Why?
| | Specimen Handling | 1 | 2014 | 153 | 0.030 |
Why?
| | Administration, Intranasal | 3 | 1989 | 75 | 0.030 |
Why?
| | In Situ Hybridization | 1 | 1994 | 292 | 0.030 |
Why?
| | Gonanes | 1 | 2013 | 27 | 0.030 |
Why?
| | Feedback, Physiological | 1 | 2013 | 68 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1994 | 181 | 0.030 |
Why?
| | Ascorbic Acid | 1 | 1994 | 110 | 0.030 |
Why?
| | Iron | 3 | 1989 | 232 | 0.030 |
Why?
| | Epithelial Cells | 1 | 1998 | 946 | 0.030 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 36 | 0.030 |
Why?
| | Patient Discharge | 1 | 2018 | 770 | 0.030 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 59 | 0.030 |
Why?
| | Anemia, Aplastic | 3 | 1983 | 30 | 0.030 |
Why?
| | Cetuximab | 1 | 2013 | 90 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 33 | 0.030 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 122 | 0.030 |
Why?
| | Individuality | 1 | 1994 | 146 | 0.030 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 29 | 0.030 |
Why?
| | Flow Cytometry | 3 | 2008 | 1075 | 0.030 |
Why?
| | Precision Medicine | 1 | 2016 | 335 | 0.030 |
Why?
| | Pathology, Clinical | 1 | 2012 | 32 | 0.030 |
Why?
| | Mice, Inbred C57BL | 4 | 2010 | 4682 | 0.030 |
Why?
| | Mechlorethamine | 3 | 1982 | 63 | 0.030 |
Why?
| | Vaccines | 1 | 1997 | 375 | 0.020 |
Why?
| | Benzoates | 1 | 1972 | 38 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 82 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2012 | 227 | 0.020 |
Why?
| | Coloring Agents | 1 | 2012 | 72 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 171 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 312 | 0.020 |
Why?
| | Hawaii | 1 | 1991 | 38 | 0.020 |
Why?
| | Mitosis | 1 | 1992 | 164 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 283 | 0.020 |
Why?
| | Prednisone | 1 | 1972 | 229 | 0.020 |
Why?
| | DNA Repair | 1 | 2013 | 184 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 229 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 190 | 0.020 |
Why?
| | Dermatology | 1 | 2012 | 86 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 328 | 0.020 |
Why?
| | Melphalan | 3 | 1986 | 29 | 0.020 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 1 | 2010 | 22 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 1994 | 356 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 552 | 0.020 |
Why?
| | DNA Damage | 1 | 2013 | 351 | 0.020 |
Why?
| | California | 1 | 1991 | 351 | 0.020 |
Why?
| | Sex Ratio | 1 | 1990 | 14 | 0.020 |
Why?
| | Megakaryocytes | 2 | 1981 | 29 | 0.020 |
Why?
| | Pigmentation | 1 | 2010 | 54 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 534 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1143 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 134 | 0.020 |
Why?
| | DNA Primers | 1 | 2011 | 508 | 0.020 |
Why?
| | Penicillin V | 1 | 1989 | 3 | 0.020 |
Why?
| | Imidazoles | 1 | 2010 | 203 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1331 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2010 | 139 | 0.020 |
Why?
| | Body Surface Area | 1 | 2009 | 27 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2010 | 151 | 0.020 |
Why?
| | Deferoxamine | 1 | 1989 | 17 | 0.020 |
Why?
| | Colorado | 2 | 2009 | 4092 | 0.020 |
Why?
| | Mouth | 1 | 1989 | 69 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 1989 | 115 | 0.020 |
Why?
| | Lithium Chloride | 2 | 1986 | 11 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 742 | 0.020 |
Why?
| | Temperature | 3 | 1981 | 564 | 0.020 |
Why?
| | Abdomen | 1 | 2009 | 99 | 0.020 |
Why?
| | Anemia | 2 | 1982 | 143 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 20 | 0.020 |
Why?
| | Eye Color | 1 | 1988 | 3 | 0.020 |
Why?
| | Age Factors | 3 | 1990 | 2886 | 0.020 |
Why?
| | Upper Extremity | 1 | 2009 | 83 | 0.020 |
Why?
| | Hair Color | 1 | 1988 | 10 | 0.020 |
Why?
| | Surgical Procedures, Operative | 1 | 1971 | 206 | 0.020 |
Why?
| | Interferon-beta | 1 | 2008 | 79 | 0.020 |
Why?
| | Chlorides | 2 | 1986 | 127 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 492 | 0.020 |
Why?
| | Cimetidine | 1 | 1988 | 11 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 132 | 0.020 |
Why?
| | Liver Neoplasms | 2 | 2006 | 504 | 0.020 |
Why?
| | Contusions | 1 | 2007 | 19 | 0.020 |
Why?
| | Nausea | 1 | 2007 | 99 | 0.020 |
Why?
| | Leukopenia | 2 | 1991 | 27 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 141 | 0.020 |
Why?
| | Prospective Studies | 4 | 2005 | 6198 | 0.020 |
Why?
| | Molecular Weight | 2 | 1979 | 328 | 0.020 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 12 | 0.020 |
Why?
| | Laparotomy | 1 | 2007 | 101 | 0.020 |
Why?
| | Vaccines, Combined | 2 | 1997 | 46 | 0.020 |
Why?
| | Double-Blind Method | 3 | 1998 | 1656 | 0.020 |
Why?
| | Hydroxyurea | 2 | 1984 | 30 | 0.020 |
Why?
| | Hemoglobins | 1 | 1988 | 308 | 0.020 |
Why?
| | Erythrocytes | 3 | 1981 | 568 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 787 | 0.020 |
Why?
| | Intestine, Small | 1 | 2007 | 121 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2005 | 6 | 0.020 |
Why?
| | MART-1 Antigen | 1 | 2005 | 10 | 0.020 |
Why?
| | Tomography, Emission-Computed | 1 | 1986 | 58 | 0.020 |
Why?
| | Lower Extremity | 1 | 2009 | 334 | 0.020 |
Why?
| | Culture Media | 4 | 1977 | 155 | 0.020 |
Why?
| | Antigens, CD | 1 | 2008 | 440 | 0.020 |
Why?
| | Fatigue | 1 | 2007 | 294 | 0.020 |
Why?
| | Metaproterenol | 1 | 1985 | 2 | 0.020 |
Why?
| | Extremities | 1 | 2006 | 111 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 1988 | 307 | 0.020 |
Why?
| | Blood Platelets | 3 | 1974 | 326 | 0.020 |
Why?
| | Neoplasm Proteins | 2 | 2005 | 385 | 0.020 |
Why?
| | Platelet Count | 2 | 1986 | 79 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 813 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2008 | 435 | 0.020 |
Why?
| | Survivors | 1 | 2008 | 415 | 0.020 |
Why?
| | Spleen | 2 | 1981 | 485 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2009 | 636 | 0.010 |
Why?
| | Constriction, Pathologic | 1 | 1985 | 207 | 0.010 |
Why?
| | Remission Induction | 2 | 1995 | 233 | 0.010 |
Why?
| | Syndrome | 1 | 1985 | 330 | 0.010 |
Why?
| | Nucleoproteins | 1 | 1984 | 27 | 0.010 |
Why?
| | Emergencies | 1 | 1985 | 143 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 332 | 0.010 |
Why?
| | Administration, Topical | 1 | 1984 | 137 | 0.010 |
Why?
| | Podophyllotoxin | 1 | 1984 | 7 | 0.010 |
Why?
| | Epinephrine | 1 | 1985 | 163 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 79 | 0.010 |
Why?
| | Neuropilin-1 | 1 | 2003 | 9 | 0.010 |
Why?
| | Heart Arrest | 2 | 1984 | 293 | 0.010 |
Why?
| | Etoposide | 1 | 1984 | 149 | 0.010 |
Why?
| | Fibula | 1 | 1983 | 40 | 0.010 |
Why?
| | Cell Nucleolus | 1 | 1983 | 17 | 0.010 |
Why?
| | Cell Nucleus | 2 | 1984 | 552 | 0.010 |
Why?
| | Enterobacter | 1 | 1983 | 7 | 0.010 |
Why?
| | Ultrasonography | 1 | 2006 | 635 | 0.010 |
Why?
| | Antibodies, Antinuclear | 1 | 1983 | 58 | 0.010 |
Why?
| | Busulfan | 1 | 1982 | 14 | 0.010 |
Why?
| | Klebsiella pneumoniae | 1 | 1983 | 41 | 0.010 |
Why?
| | Erythropoiesis | 1 | 1982 | 33 | 0.010 |
Why?
| | Bleomycin | 1 | 1984 | 228 | 0.010 |
Why?
| | Hypoglycemia | 1 | 2007 | 386 | 0.010 |
Why?
| | Cytoplasm | 1 | 1983 | 255 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 2764 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1982 | 158 | 0.010 |
Why?
| | Transplantation, Autologous | 4 | 1984 | 175 | 0.010 |
Why?
| | Pain | 1 | 2007 | 701 | 0.010 |
Why?
| | Glucose | 1 | 2007 | 899 | 0.010 |
Why?
| | Schistosomiasis | 1 | 1982 | 37 | 0.010 |
Why?
| | Choriocarcinoma | 1 | 1981 | 8 | 0.010 |
Why?
| | Glycogen Storage Disease Type I | 1 | 1980 | 5 | 0.010 |
Why?
| | Pregnancy | 2 | 2004 | 5503 | 0.010 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2001 | 182 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1024 | 0.010 |
Why?
| | Pseudomonas aeruginosa | 1 | 1983 | 298 | 0.010 |
Why?
| | Thymidine Kinase | 1 | 2000 | 14 | 0.010 |
Why?
| | Blood Transfusion | 2 | 1974 | 265 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1980 | 119 | 0.010 |
Why?
| | Retinoblastoma Protein | 1 | 2000 | 52 | 0.010 |
Why?
| | Doxycycline | 1 | 2000 | 54 | 0.010 |
Why?
| | Luciferases | 1 | 2000 | 142 | 0.010 |
Why?
| | Chromosomes, Human, 4-5 | 1 | 1979 | 1 | 0.010 |
Why?
| | Anemia, Macrocytic | 1 | 1979 | 4 | 0.010 |
Why?
| | Simplexvirus | 1 | 2000 | 80 | 0.010 |
Why?
| | Thrombocytosis | 1 | 1979 | 6 | 0.010 |
Why?
| | Sepsis | 1 | 1985 | 507 | 0.010 |
Why?
| | Electrophoresis, Cellulose Acetate | 1 | 1979 | 1 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 124 | 0.010 |
Why?
| | Pronase | 1 | 1979 | 5 | 0.010 |
Why?
| | Autoantibodies | 2 | 1984 | 1350 | 0.010 |
Why?
| | Deoxyribonucleases | 1 | 1979 | 21 | 0.010 |
Why?
| | Ribonucleases | 1 | 1979 | 52 | 0.010 |
Why?
| | Plasmids | 1 | 2000 | 343 | 0.010 |
Why?
| | Trypsin | 1 | 1979 | 66 | 0.010 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 1979 | 36 | 0.010 |
Why?
| | Remission, Spontaneous | 2 | 1977 | 37 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 3 | 1984 | 396 | 0.010 |
Why?
| | Hematocrit | 2 | 1977 | 86 | 0.010 |
Why?
| | Anemia, Hypochromic | 1 | 1977 | 2 | 0.010 |
Why?
| | Nitrogen | 1 | 1979 | 143 | 0.010 |
Why?
| | Hypocalcemia | 3 | 1984 | 30 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 863 | 0.010 |
Why?
| | Pneumonia | 1 | 1983 | 563 | 0.010 |
Why?
| | Species Specificity | 1 | 1979 | 541 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1979 | 507 | 0.010 |
Why?
| | Trans-Activators | 1 | 2000 | 366 | 0.010 |
Why?
| | Agar | 1 | 1977 | 11 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 613 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 2 | 1983 | 1006 | 0.010 |
Why?
| | Pericardium | 1 | 1976 | 50 | 0.010 |
Why?
| | Groin | 1 | 1995 | 13 | 0.010 |
Why?
| | Subclavian Vein | 1 | 1995 | 14 | 0.010 |
Why?
| | Patient Compliance | 2 | 1989 | 524 | 0.010 |
Why?
| | Blood Protein Electrophoresis | 1 | 1975 | 7 | 0.010 |
Why?
| | Typhoid-Paratyphoid Vaccines | 1 | 1975 | 4 | 0.010 |
Why?
| | Pyrogens | 1 | 1975 | 55 | 0.010 |
Why?
| | Iron Radioisotopes | 1 | 1974 | 3 | 0.010 |
Why?
| | Cobalt Radioisotopes | 1 | 1974 | 6 | 0.010 |
Why?
| | Pyelonephritis | 1 | 1974 | 7 | 0.010 |
Why?
| | Dialysis | 1 | 1974 | 17 | 0.010 |
Why?
| | Hospitals, University | 1 | 1995 | 169 | 0.010 |
Why?
| | Centrifugation | 1 | 1974 | 31 | 0.010 |
Why?
| | Salmonella | 1 | 1975 | 54 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1995 | 113 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 1981 | 1735 | 0.010 |
Why?
| | Skin Physiological Phenomena | 1 | 1994 | 26 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 92 | 0.010 |
Why?
| | Photoperiod | 1 | 1994 | 48 | 0.010 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1974 | 81 | 0.010 |
Why?
| | Virus Diseases | 1 | 1976 | 195 | 0.010 |
Why?
| | Multiple Myeloma | 1 | 1974 | 98 | 0.010 |
Why?
| | Hydrocortisone | 1 | 1975 | 267 | 0.010 |
Why?
| | Asthma | 1 | 1985 | 2021 | 0.010 |
Why?
| | Procarbazine | 1 | 1972 | 8 | 0.010 |
Why?
| | Diseases in Twins | 1 | 1973 | 174 | 0.010 |
Why?
| | Doxorubicin | 2 | 1984 | 286 | 0.010 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1972 | 70 | 0.010 |
Why?
| | Drug Combinations | 1 | 1972 | 286 | 0.010 |
Why?
| | Length of Stay | 1 | 1995 | 957 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2322 | 0.010 |
Why?
| | Perfusion | 1 | 1970 | 147 | 0.010 |
Why?
| | Skin | 1 | 1994 | 653 | 0.010 |
Why?
| | Taurodeoxycholic Acid | 1 | 1989 | 1 | 0.010 |
Why?
| | Debridement | 1 | 1989 | 71 | 0.010 |
Why?
| | Mouth Mucosa | 1 | 1989 | 79 | 0.010 |
Why?
| | Ferritins | 1 | 1989 | 52 | 0.000 |
Why?
| | Placebos | 1 | 1989 | 197 | 0.000 |
Why?
| | Antibody Formation | 1 | 1970 | 266 | 0.000 |
Why?
| | Bone Marrow Examination | 2 | 1979 | 6 | 0.000 |
Why?
| | Wounds and Injuries | 1 | 1995 | 674 | 0.000 |
Why?
| | Peak Expiratory Flow Rate | 1 | 1985 | 33 | 0.000 |
Why?
| | Prostaglandins E | 1 | 1985 | 44 | 0.000 |
Why?
| | Saudi Arabia | 1 | 1985 | 6 | 0.000 |
Why?
| | Lactoferrin | 1 | 1985 | 27 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1995 | 2122 | 0.000 |
Why?
| | Immunodiffusion | 1 | 1984 | 9 | 0.000 |
Why?
| | Polysaccharides, Bacterial | 1 | 1985 | 66 | 0.000 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1984 | 49 | 0.000 |
Why?
| | Aerosols | 1 | 1985 | 150 | 0.000 |
Why?
| | Antigen-Antibody Complex | 1 | 1984 | 84 | 0.000 |
Why?
| | Teniposide | 1 | 1984 | 3 | 0.000 |
Why?
| | Chromosomes, Human, 21-22 and Y | 1 | 1984 | 4 | 0.000 |
Why?
| | Tissue Preservation | 1 | 1984 | 11 | 0.000 |
Why?
| | Daunorubicin | 1 | 1984 | 24 | 0.000 |
Why?
| | Melanoma-Specific Antigens | 1 | 1983 | 2 | 0.000 |
Why?
| | Syncope | 1 | 1984 | 38 | 0.000 |
Why?
| | False Negative Reactions | 1 | 1983 | 48 | 0.000 |
Why?
| | Cell Line | 2 | 1983 | 2629 | 0.000 |
Why?
| | Phosphates | 1 | 1984 | 155 | 0.000 |
Why?
| | Heterozygote | 1 | 1983 | 250 | 0.000 |
Why?
| | Lomustine | 1 | 1982 | 14 | 0.000 |
Why?
| | Fever | 1 | 1984 | 280 | 0.000 |
Why?
| | Egypt | 1 | 1982 | 10 | 0.000 |
Why?
| | Heart Rate | 1 | 1985 | 710 | 0.000 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1981 | 188 | 0.000 |
Why?
| | Tachycardia | 1 | 1981 | 50 | 0.000 |
Why?
| | Mice, Inbred Strains | 1 | 1981 | 398 | 0.000 |
Why?
| | Cell Separation | 1 | 1981 | 290 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1981 | 350 | 0.000 |
Why?
| | Fanconi Anemia | 1 | 1979 | 9 | 0.000 |
Why?
| | Blood Pressure | 1 | 1985 | 1531 | 0.000 |
Why?
| | Blood Cells | 1 | 1979 | 38 | 0.000 |
Why?
| | Complement System Proteins | 1 | 1981 | 282 | 0.000 |
Why?
| | Cold Temperature | 1 | 1979 | 125 | 0.000 |
Why?
| | Electrocardiography | 1 | 1981 | 561 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1982 | 489 | 0.000 |
Why?
| | Blood | 1 | 1977 | 94 | 0.000 |
Why?
| | Pericardial Effusion | 1 | 1976 | 21 | 0.000 |
Why?
| | Autopsy | 1 | 1976 | 83 | 0.000 |
Why?
| | Cell Count | 1 | 1977 | 303 | 0.000 |
Why?
| | DNA | 1 | 1983 | 1350 | 0.000 |
Why?
| | Child, Preschool | 2 | 1980 | 9121 | 0.000 |
Why?
| | Alpha-Globulins | 1 | 1975 | 20 | 0.000 |
Why?
| | Recurrence | 1 | 1977 | 925 | 0.000 |
Why?
| | Cytogenetics | 1 | 1973 | 11 | 0.000 |
Why?
| | Periodicity | 1 | 1973 | 54 | 0.000 |
Why?
| | Muramidase | 1 | 1973 | 72 | 0.000 |
Why?
| | Arm | 1 | 1972 | 104 | 0.000 |
Why?
| | Chronic Disease | 1 | 1977 | 1579 | 0.000 |
Why?
| | Leg | 1 | 1972 | 224 | 0.000 |
Why?
| | Splenectomy | 1 | 1970 | 51 | 0.000 |
Why?
| | Immunity | 1 | 1970 | 121 | 0.000 |
Why?
| | Swine | 1 | 1970 | 687 | 0.000 |
Why?
| | Sheep | 1 | 1970 | 761 | 0.000 |
Why?
| | Immunization | 1 | 1970 | 397 | 0.000 |
Why?
|
|
Robinson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|